{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T17:53:25Z","timestamp":1765821205803,"version":"3.48.0"},"reference-count":54,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T00:00:00Z","timestamp":1635897600000},"content-version":"unspecified","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018353","name":"European Crohn\u2019s and Colitis Organisation","doi-asserted-by":"crossref","award":["ECCO 2021"],"award-info":[{"award-number":["ECCO 2021"]}],"id":[{"id":"10.13039\/100018353","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2021,10,15]]},"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Anti-tumour necrosis factor (TNF) therapy has greatly improved treatment outcomes in patients with inflammatory bowel disease (IBD), but long-term use is associated with cutaneous reactions, susceptibility to infections and frequent injections or hospital visits. Several non-controlled studies have demonstrated that dose reduction is feasible for a subset of patients, provided that early detection of a disease flare is possible. Here, we aim to compare the effectiveness of interval lengthening with standard dosing in maintaining remission in young patients with IBD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>In this international, prospective, non-inferiority, partially randomised patient preference trial, we aim to recruit 148 patients aged 12\u201325 years with luminal Crohn\u2019s disease or ulcerative colitis in sustained remission (ie, three consecutive in-range faecal calprotectin (FC) results or recently confirmed endoscopic remission). In the interventional arm, the dosing interval will be lengthened from 8 to 12 weeks for infliximab users and from 2 to 3 weeks for adalimumab users. In the control group, standard dosing will be continued. Rapid tests will be performed for FC every 4 weeks and for anti-TNF trough levels every 12 weeks. The primary outcome is the cumulative incidence of out-of-range FC results at 48-week follow-up. Secondary endpoints include time to get out-of-range FC results, cumulative incidence of adverse effects, proportion of patients progressing to loss of response and identification of predictors of successful interval lengthening.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The protocol has been approved by the Medical Ethics Review Committee of the University Medical Centre Groningen and is pending at the other participating centres. Results will be disseminated in peer-reviewed journals and presented at scientific meetings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      EudraCT number: 2020-001811-26; ClinicalTrials.gov Identifier:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04646187\">NCT04646187<\/jats:ext-link>\n                      . Protocol version 4, date 17 September 2021.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2021-054154","type":"journal-article","created":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T12:33:51Z","timestamp":1635942831000},"page":"e054154","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy of anti-TNF dosing interval lengthening in adolescents and young adults with inflammatory bowel disease in sustained remission (FREE-study): protocol for a partially randomised patient preference trial"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct04646187","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6530-2198","authenticated-orcid":false,"given":"Marleen","family":"Bouhuys","sequence":"first","affiliation":[{"name":"Department of Paediatric Gastroenterology, Hepatology and Nutrition, University Medical Centre Groningen, Beatrix Childrens Hospital, Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Willem S","family":"Lexmond","sequence":"additional","affiliation":[{"name":"Department of Paediatric Gastroenterology, Hepatology and Nutrition, University Medical Centre Groningen, Beatrix Childrens Hospital, Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerard","family":"Dijkstra","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Medical Centre Groningen, Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Triana","family":"Lobat\u00f3n","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, University Hospital Ghent, Gent, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edouard","family":"Louis","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Central University Hospital of Liege, Liege, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"van Biervliet","sequence":"additional","affiliation":[{"name":"Department of Paediatric Gastroenterology, University Hospital Ghent, Gent, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6629-318X","authenticated-orcid":false,"given":"Henk","family":"Groen","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, University Medical Centre Groningen, Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"Guardiola","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Bellvitge University Hospital, IDIBELL, L\"Hospitalet de Llobregat, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3867-2665","authenticated-orcid":false,"given":"Patrick van","family":"Rheenen","sequence":"additional","affiliation":[{"name":"Department of Paediatric Gastroenterology, Hepatology and Nutrition, University Medical Centre Groningen, Beatrix Childrens Hospital, Groningen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,11,3]]},"reference":[{"key":"2025121509495032000_11.11.e054154.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2012.05.015"},{"key":"2025121509495032000_11.11.e054154.2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjz180"},{"key":"2025121509495032000_11.11.e054154.3","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/apt.15685","article-title":"Systematic review and meta-analysis: efficacy and safety of early biologic treatment in adult and paediatric patients with Crohn\"s disease","volume":"51","author":"Ungaro","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"2025121509495032000_11.11.e054154.4","doi-asserted-by":"crossref","first-page":"121","DOI":"10.5223\/pghn.2020.23.2.121","article-title":"Long-Term efficacy of anti-tumor necrosis factor agents in pediatric luminal Crohn\"s disease: a systematic review of real-world evidence studies","volume":"23","author":"van Rheenen","year":"2020","journal-title":"Pediatr Gastroenterol Hepatol Nutr"},{"key":"2025121509495032000_11.11.e054154.5","doi-asserted-by":"crossref","first-page":"S427","DOI":"10.1093\/ecco-jcc\/jjy222.745","article-title":"P621 real-world effectiveness and safety of vedolizumab and anti-TNF in biologic-naive Crohn\u2019s disease patients: results from the EVOLVE study","volume":"13","author":"Bressler","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2025121509495032000_11.11.e054154.6","doi-asserted-by":"crossref","first-page":"S400","DOI":"10.1093\/ecco-jcc\/jjy222.697","article-title":"P573 real-world effectiveness and safety of vedolizumab and anti-TNF in biologic-naive ulcerative colitis patients: results from the evolve study","volume":"13","author":"Yarur","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2025121509495032000_11.11.e054154.7","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izz078"},{"key":"2025121509495032000_11.11.e054154.8","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/ajg.2016.54","article-title":"The risk of relapse after anti-TNF discontinuation in inflammatory bowel disease: systematic review and meta-analysis","volume":"111","author":"Gisbert","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"2025121509495032000_11.11.e054154.9","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/ecco-jcc\/jjx101","article-title":"European crohn\"s and colitis organisation topical review on treatment withdrawal [\"exit strategies\"] in inflammatory bowel disease","volume":"12","author":"Doherty","year":"2018","journal-title":"J Crohns Colitis"},{"key":"2025121509495032000_11.11.e054154.10","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjv206"},{"key":"2025121509495032000_11.11.e054154.11","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/apt.13299","article-title":"Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: potential implications for dosing in clinical practice","volume":"42","author":"Buurman","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"2025121509495032000_11.11.e054154.12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212423"},{"key":"2025121509495032000_11.11.e054154.13","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1111\/apt.13964","article-title":"Dose de-escalation to adalimumab 40 mg every 3 weeks in patients with Crohn\"s disease - a nested case-control study","volume":"45","author":"Van Steenbergen","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"2025121509495032000_11.11.e054154.14","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.dld.2018.10.022","article-title":"Dose de-escalation to adalimumab 40 mg every three weeks in patients with inflammatory bowel disease-A multicenter, retrospective, observational study","volume":"51","author":"Pouillon","year":"2019","journal-title":"Dig Liver Dis"},{"key":"2025121509495032000_11.11.e054154.15","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.02.031"},{"key":"2025121509495032000_11.11.e054154.16","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9082646","article-title":"Early intervention in ulcerative colitis: ready for prime time?","volume":"9","author":"Solitano","year":"2020","journal-title":"J Clin Med"},{"key":"2025121509495032000_11.11.e054154.17","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-314519"},{"key":"2025121509495032000_11.11.e054154.18","doi-asserted-by":"crossref","first-page":"S024","DOI":"10.1093\/ecco-jcc\/jjy222.032","article-title":"OP35 endoscopic and deep remission at 1 year prevents disease progression in early crohn\u2019s disease: long-term data from CALM","volume":"13","author":"Yzet","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2025121509495032000_11.11.e054154.19","doi-asserted-by":"publisher","DOI":"10.1002\/art.34343"},{"key":"2025121509495032000_11.11.e054154.20","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2015.233"},{"key":"2025121509495032000_11.11.e054154.21","doi-asserted-by":"publisher","DOI":"10.3109\/00365521.2014.886719"},{"key":"2025121509495032000_11.11.e054154.22","first-page":"1386","article-title":"Predicting endoscopic crohn\"s disease activity before and after induction therapy in children: a comprehensive assessment of PCDAI, CRP, and fecal calprotectin","volume":"21","author":"Zubin","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"2025121509495032000_11.11.e054154.23","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/apt.15016","article-title":"Response to treatment is more important than disease severity at diagnosis for prediction of early relapse in new-onset paediatric crohn\"s disease","volume":"48","author":"Ziv-Baran","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2025121509495032000_11.11.e054154.24","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1053\/j.gastro.2011.09.034","article-title":"Maintenance of remission among patients with crohn\"s disease on antimetabolite therapy after infliximab therapy is stopped","volume":"142","author":"Louis","year":"2012","journal-title":"Gastroenterology"},{"key":"2025121509495032000_11.11.e054154.25","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.gastrohep.2018.05.029","article-title":"Recommendations of the spanish working group on crohn\"s disease and ulcerative colitis (GETECCU) on the utility of the determination of faecal calprotectin in inflammatory bowel disease","volume":"41","author":"Guardiola","year":"2018","journal-title":"Gastroenterol Hepatol"},{"key":"2025121509495032000_11.11.e054154.26","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1097\/MIB.0000000000001082","article-title":"Clinical utility of fecal calprotectin monitoring in asymptomatic patients with inflammatory bowel disease: a systematic review and practical guide","volume":"23","author":"Heida","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"2025121509495032000_11.11.e054154.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2013.05.005"},{"key":"2025121509495032000_11.11.e054154.28","doi-asserted-by":"crossref","first-page":"1835-1844.e6","DOI":"10.1016\/j.cgh.2020.08.022","article-title":"Normalization of fecal calprotectin within 12 months of diagnosis is associated with reduced risk of disease progression in patients with crohn\"s disease","volume":"19","author":"Plevris","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025121509495032000_11.11.e054154.29","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0b013e3182802b6e"},{"key":"2025121509495032000_11.11.e054154.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2014.06.020"},{"key":"2025121509495032000_11.11.e054154.31","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32641-7"},{"key":"2025121509495032000_11.11.e054154.32","doi-asserted-by":"crossref","first-page":"2098293","DOI":"10.1155\/2017\/2098293","article-title":"Fecal calprotectin: a reliable predictor of mucosal healing after treatment for active ulcerative colitis","volume":"2017","author":"Kristensen","year":"2017","journal-title":"Gastroenterol Res Pract"},{"key":"2025121509495032000_11.11.e054154.33","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000069"},{"key":"2025121509495032000_11.11.e054154.34","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13731"},{"key":"2025121509495032000_11.11.e054154.35","unstructured":"European Medicines Agency . Remicade 100 mg powder for concentrate for solution for infusion - summary of product characteristics (SPC) - (eMC), 2009. Available: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/remicade-epar-product-information_en.pdf [Accessed 31 Mar 2020]."},{"key":"2025121509495032000_11.11.e054154.36","unstructured":"European Medicines Agency . Humira 20 mg solution for injection in pre-filled syringe - summary of product characteristics (SPC) - (eMC), 2008. Available: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/humira-epar-product-information_en.pdf [Accessed 31 Mar 2020]."},{"key":"2025121509495032000_11.11.e054154.37","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/apt.15097","article-title":"Review article: managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease","volume":"49","author":"Shivaji","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"2025121509495032000_11.11.e054154.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208"},{"key":"2025121509495032000_11.11.e054154.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"2025121509495032000_11.11.e054154.40","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-016-0410-1"},{"key":"2025121509495032000_11.11.e054154.41","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s40266-019-00712-6","article-title":"Patients\" attitudes towards deprescribing alpha-blockers and their willingness to participate in a discontinuation trial","volume":"36","author":"Edelman","year":"2019","journal-title":"Drugs Aging"},{"key":"2025121509495032000_11.11.e054154.42","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.sapharm.2020.11.004","article-title":"Cross-cultural adaptation and psychometric validation of the revised patients\" attitudes towards deprescribing (rPATD) questionnaire in French","volume":"17","author":"Roux","year":"2021","journal-title":"Res Social Adm Pharm"},{"key":"2025121509495032000_11.11.e054154.43","unstructured":"de Juan Rold\u00e1n J , Gavil\u00e1n Moral E , Garc\u00eda Ruiz A . Estudio de validaci\u00f3n al castellano del cuestionario revised patients\u2019 attitudes towards deprescribing (rPATD) para evaluar las actitudes de los pacientes hacia la deprescripci\u00f3n. Barcelona: XXXVIII Congreso semFYC, 2018."},{"key":"2025121509495032000_11.11.e054154.44","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.cgh.2017.06.007","article-title":"Agreement between home-based measurement of stool calprotectin and ELISA results for monitoring inflammatory bowel disease activity","volume":"15","author":"Heida","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025121509495032000_11.11.e054154.45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0214751","article-title":"Head-to-head comparison of three stool calprotectin tests for home use","volume":"14","author":"Haisma","year":"2019","journal-title":"PLoS One"},{"key":"2025121509495032000_11.11.e054154.46","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.05.029"},{"key":"2025121509495032000_11.11.e054154.47","doi-asserted-by":"publisher","DOI":"10.1136\/gut.43.1.29"},{"key":"2025121509495032000_11.11.e054154.48","doi-asserted-by":"publisher","DOI":"10.1097\/00005176-199105000-00005"},{"key":"2025121509495032000_11.11.e054154.49","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20520"},{"key":"2025121509495032000_11.11.e054154.50","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjw144"},{"key":"2025121509495032000_11.11.e054154.51","article-title":"Are we addressing the top 10 research priorities in IBD?","volume":"2","author":"Geldof","year":"2020","journal-title":"Frontline Gastroenterol"},{"key":"2025121509495032000_11.11.e054154.52","unstructured":"Schultz KF , GD A . Boosting recruitment to randomised controlled trials. In: Essential concepts in clinical research. 2nd edn. Edinburgh: Elsevier limited, 2019: 112\u20133."},{"key":"2025121509495032000_11.11.e054154.53","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.164.2.201"},{"key":"2025121509495032000_11.11.e054154.54","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.281053"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2021-054154","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T17:50:01Z","timestamp":1765821001000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2021-054154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":54,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,11,3]]},"published-print":{"date-parts":[[2021,11]]}},"alternative-id":["10.1136\/bmjopen-2021-054154"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2021-054154","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2021,11]]}}}